Evidence map›Paper›PMID 42302965›Full record

ArticleTransplantation and cellular therapy2026

Prolonged Cytopenia After Idecabtagene Vicleucel for Multiple Myeloma is Associated with Poor Overall Survival.

Gurbakhash Kaur, Jennifer Logue, Ruta Brazauskas, Temitope Oloyede, Muhammad Bilal Abid, Sairah Ahmed, Mahmoud Aljurf, Rahul Banerjee, Asad Bashey, Amer M Beitinjaneh and 21 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Transplantation and cellular therapy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

31 authors.

Gurbakhash KaurMyeloma, Waldenstrom's and Amyloidosis Program, Simmons Comprehensive Cancer Center, UT Southwestern Medical Center, Dallas, Texas.
Jennifer LogueH. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida.
Ruta BrazauskasDivision of Biostatistics, Data Science Institute, Medical College of Wisconsin, Milwaukee, Wisconsin; Center for International Blood and Marrow Transplant Research (CIBMTR), Medical College of Wisconsin, Milwaukee, Wisconsin.
Temitope OloyedeCenter for International Blood and Marrow Transplant Research (CIBMTR), Medical College of Wisconsin, Milwaukee, Wisconsin.
Muhammad Bilal AbidDivision of Cellular Immunotherapy and Blood & Marrow Transplant, Texas Tech University Health Science Center School of Medicine, Lubbock, Texas.
Sairah AhmedDepartment of Lymphoma/Myeloma and Stem Cell Transplantation, MD Anderson Cancer Center, University of Texas, Houston, Texas.
Mahmoud AljurfDepartment of Hematology, King Faisal Specialist Hospital Center and Research, Riyadh, Saudi Arabia.
Rahul BanerjeeDivision of Medical Oncology, University of Washington, Seattle, Washington; Clinical Research Division, Fred Hutchinson Cancer Center, Seattle, Washington.
Asad BasheyBlood and Marrow Transplant Program, Northside Hospital, Atlanta, Georgia.
Amer M BeitinjanehDivision of Transplantation and Cellular Therapy, Sylvester Comprehensive Cancer Center, University of Miami Hospital and Clinics, Miami, Florida.
Natalie S CallanderDivision of Hematology, Medical Oncology and Palliative Care, University of Wisconsin Carbone Cancer Center, Madison, Wisconsin.
Paul CastilloUniversity of Florida Health Shands Children's Hospital, Gainesville, Florida.
Bhagirathbhai DholariaVanderbilt University Medical Center, Nashville, Tennessee.
Scott R GoldsmithDepartment of Hematology & Hematopoietic Transplantation, City of Hope Comprehensive Cancer Center, Duarte, California.
Shahrukh HashmiDepartment of Medicine, Sheikh Shakhbout Medical City, Abu Dhabi, United Arab Emirates; Mayo Clinic Cancer Center, Mayo Clinic, Rochester, Minnesota; College of Medicine and Health Sciences, Khalifa University, Abu Dhabi, United Arab Emirates.
Mohamed A Kharfan-DabajaDivision of Hematology-Oncology, Blood and Marrow Transplantation Program, Mayo Clinic, Jacksonville, Florida.
Hongtao LiuDivision of Hematology, Medical Oncology and Palliative Care, University of Wisconsin Carbone Cancer Center, Madison, Wisconsin.
Hira MianDepartment of Oncology, McMaster University, Hamilton, Ontario, Canada.
Taiga NishihoriDepartment of Blood and Marrow Transplant and Cellular Immunotherapy, Moffitt Cancer Center, Tampa, Florida; Department of Oncologic Sciences, Morsani College of Medicine, University South of Florida, Tampa, Florida.
Kai RejeskiAdult Bone Marrow Transplantation Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York; Department of Medicine III - Hematology/Oncology, LMU University Hospital, LMU Munich, Munich, Germany.
Ayman SaadDepartment of Hematology, King Faisal Specialist Hospital Center and Research, Riyadh, Saudi Arabia.
Michael J SladeDivision of Oncology, Department of Medicine, Washington University in Saint Louis, St. Louis, Missouri.
Cameron J TurtleDepartment of Medicine and Health, University of Sydney, Sydney, New South Wales, Australia; Royal North Shore Hospital, St. Leonards, New South Wales, Australia; Fred Hutchinson Cancer Center, Seattle, Washington.
Dan T VoglDivision of Oncology and Hematology, Abramson Cancer Center, University of Pennsylvania, Philadelphia, Pennsylvania.
Kirsten M WilliamsAflac Cancer & Blood Disorders Center at Children's Healthcare of Atlanta, Emory University, Atlanta, Georgia.
Baldeep WirkBone Marrow Transplant Program, Virginia Commonwealth University, Richmond, Virginia.
Marcelo C PasquiniCenter for International Blood and Marrow Transplant Research (CIBMTR), Medical College of Wisconsin, Milwaukee, Wisconsin; BMT & Cellular Therapy Program, Department of Medicine, Medical College of Wisconsin, Milwaukee, Wisconsin.
Amy MoskopCenter for International Blood and Marrow Transplant Research (CIBMTR), Medical College of Wisconsin, Milwaukee, Wisconsin; Division of Pediatric Hematology/Oncology/Blood and Marrow Transplant, Department of Pediatrics, Medical College of Wisconsin, Milwaukee, Wisconsin.
Othman Salim AkhtarCenter for International Blood and Marrow Transplant Research (CIBMTR), Medical College of Wisconsin, Milwaukee, Wisconsin; BMT & Cellular Therapy Program, Department of Medicine, Medical College of Wisconsin, Milwaukee, Wisconsin. Electronic address: oakhtar@mcw.edu.
Doris K HansenDepartment of Blood & Marrow Transplant and Cellular Immunotherapy (BMT CI), Moffitt Cancer Center, Tampa, Florida.
Murali JanakiramDivision of Myeloma, Department of Hematology and HCT, City of Hope National Medical Center, Duarte, California.

Funding

X-RAY CRYSTALLOGRAPHYP30CA008748 · NCI · SLOAN-KETTERING INSTITUTE FOR CANCER RES · PI SELWYN M VICKERS · 1985 to 2026
$347.4M
Data Resource for Analyzing Blood &Marrow TransplantsU24CA076518 · NCI · MEDICAL COLLEGE OF WISCONSIN · PI Amy M Moskop, Bronwen Shaw · 1998 to 2026
$105.2M
NTP INFORMATION SYSTEMS SUPPORT27305C0011 · NIEHS · Z-TECH CORPORATION · 2007 to 2009
$4.3M
Clinical and mechanistic studies defining optimal preparative approaches to infants with IL2RG/JAK3/RAG1/RAG2 SCID: a randomized trial of busulfan dosageU01AI184132 · NIAID · NATIONAL MARROW DONOR PROGRAM · PI JEFFERY J AULETTA, Michael A Pulsipher · 2024 to 2026
$3.2M
BMT Core - Pediatric Transplantation and Cellular Therapy Consortium (PTCTC): Providing Clinical Trial Access For Children With Life Threatening DiseasesUG1HL174426 · NHLBI · NATIONAL MARROW DONOR PROGRAM · PI Leslie S Kean, Heather E Stefanski · 2024 to 2026
$513k
PROVIDE RABBITS, RATS, MICE, HAMSTERS, GERBILS, GUINEA PIGS27307C0011 · NIEHS · PI BOLEN, WAYNE · 2007 to 2007
$500k
NCI NIH HHS P30 CA008748NCI NIH HHS U24 CA076518NHLBI NIH HHS UG1 HL174426NIAID NIH HHS U01 AI184132NIEHS NIH HHS 27305C0011NIEHS NIH HHS 27307C0011NIEHS NIH HHS 27398C0011
6 · The paper itself

Abstract

Cytopenias are well-recognized toxicities of idecabtagene vicleucel (ide-cel), a chimeric antigen receptor T cell (CAR-T) therapy approved for the treatment of relapsed, refractory multiple myeloma (RRMM). However, little is known of prognostic implications of cytopenias that persist 30 to 100 days after CAR-T infusion. We report the duration, incidence, and impact on outcomes of post-CAR-T cytopenias at Day 30 and Day 100, defined as an absolute neutrophil count of <500 cells/mm

Indexed as

CAR-TCytopeniaICAHTIde-CelMultiple myeloma

Identifiers

PMID42302965
PMCPMC13560755

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.